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Abstract
Genome-wide association studies (GWAS) have been fruitful in identifying disease susceptibility loci for common and
complex diseases. A remaining question is whether we can quantify individual disease risk based on genotype data, in order
to facilitate personalized prevention and treatment for complex diseases. Previous studies have typically failed to achieve
satisfactory performance, primarily due to the use of only a limited number of confirmed susceptibility loci. Here we
propose that sophisticated machine-learning approaches with a large ensemble of markers may improve the performance
of disease risk assessment. We applied a Support Vector Machine (SVM) algorithm on a GWAS dataset generated on the
Affymetrix genotyping platform for type 1 diabetes (T1D) and optimized a risk assessment model with hundreds of markers.
We subsequently tested this model on an independent Illumina-genotyped dataset with imputed genotypes (1,008 cases
and 1,000 controls), as well as a separate Affymetrix-genotyped dataset (1,529 cases and 1,458 controls), resulting in area
under ROC curve (AUC) of ,0.84 in both datasets. In contrast, poor performance was achieved when limited to dozens of
known susceptibility loci in the SVM model or logistic regression model. Our study suggests that improved disease risk
assessment can be achieved by using algorithms that take into account interactions between a large ensemble of markers.
We are optimistic that genotype-based disease risk assessment may be feasible for diseases where a notable proportion of
the risk has already been captured by SNP arrays.
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Introduction
Genome-wide association studies (GWAS) have been success-
fully employed to interrogate the genetic architecture of common
and complex diseases [1]. Unlike traditional linkage and candidate
gene association studies, GWAS have enabled human geneticists
to examine a wide range of complex phenotypes, and have allowed
the confirmation and replication of previously unsuspected
susceptibility loci. Some of the more notable examples of success
include dozens of susceptibility loci now known to modify
individual disease risk of type 2 diabetes (T2D) [2], type 1
diabetes (T1D) [3,4], Crohn’s disease (CD) [5], as well as loci
influencing polygenic traits such as height [6–8], body mass index
[9] and dyslipidemia [10]. However, for many conditions, these
variants still explain only a small proportion of individual
differences in disease predisposition or phenotypic diversity; for
example, the 54 validated loci that influence human height
collectively only explain 4–6% of variation in the trait after
adjustment of age and sex [11], and the 31 validated susceptibility
loci for Crohn’s disease collectively only explains 20% of the
genetic risk variance [5]. Identifying most of the remaining genetic
variance still represents a challenge, albeit tractable, for the
foreseeable future.
Besides identifying genes influencing disease susceptibility or
phenotypic variation, another often suggested utility of GWAS is
that these discoveries will facilitate implementation of personalized
medicine, in which preventive and therapeutic interventions for
complex diseases are tailored to individuals based on their genetic
make-up, as can be determined by genome-wide genotyping
profiles on a SNP-based array. The latter promise is now routinely
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factor has already been characterized; however, for common and
complex diseases, where multiple loci work together to increase
disease risk, the application of personalized medicine may not be
as straightforward. In fact, several studies have been recently
published on the assessment of risk for common diseases using
multiple genetic variants (reviewed in [12–16]). However, a
consistent theme from these studies is that disease assessment
methods so far show limited predictive value, and the performance
of these studies is far below what would be considered clinically
feasible or practical. For example, at least four studies have been
conducted to use several ‘‘validated’’ variants for risk prediction of
type 2 diabetes (T2D) [17–20]. The AUC (area under the receiver
operating characteristic curve) scores for the T2D studies range
from 0.55 to 0.60, indicating that the prediction is only slightly
better than chance; however, they also indicate that the use of
more markers should lead to improvement of predictive
performance. A more recent study on multiple human diseases
reported slightly higher AUC scores for Age-related Macular
Degeneration (AMD) and Crohn’s Disease (CD), but the results
are still largely negative; in fact, the authors cautioned that the
scientific community should avoid ‘‘overstating the value of
association findings in terms of personalized medicine’’ [15].
Other similar negative studies have been conducted for a variety of
human diseases and complex traits, such as height [11], coronary
heart disease [21] and cardiovascular diseases [22], although
positive studies have been reported for AMD when combining
genetic, demographic, and environmental variables [23]. Alto-
gether, these observations have triggered concern about the
potential value of individual-based disease risk assessment, at least
for the time being.
Our view is that since the majority of risk factors for human
diseases or complex traits have yet to be identified, the failure of
previous studies on predicting individual disease risk is not
unexpected: First, all these studies have investigated only a limited
number of susceptibility variants that were confirmed in previous
GWAS. As previously discussed, these validated susceptibility loci
typically only explain a small proportion of the genetic risk
underlying phenotypic variance. Therefore, the omission of the
vast majority of genuine susceptibility loci that are yet to be
validated from GWAS precludes success, since most of the
informative markers are absent from prediction model. For
example, none of the four T2D risk assessment studies [17–20]
used more than 20 SNPs; we do not expect that any such study
would yield satisfactory results from a handful of loci, which
collectively explain only a minor fraction of disease risk. We
however acknowledge that the reason why most genetic variants
have not been identified is because the first generation of GWAS
were powered to detect variants of large effect sizes; with the ever
increasing sample sizes in GWAS, more loci will be discovered and
validated in the future. Second, only relatively simple statistical
approaches, such as additive genotype scores (unweighted or
weighted number of risk alleles) or logistic regression assuming
independence between variants, have been applied in previous
studies. These approaches, although widely used in statistical
genetics, do not take into account the complex relationships or
interactions between multiple loci contributing to disease risk. In
fact, regression analysis is optimized for the purpose of estimating
the effects of predictor variables, unlike other more sophisticated
machine-learning approaches (especially maximum-margin ap-
proaches) for the sole purpose of classification or discrimination.
Finally, the whole-genome genotype data in the diseases from
these previous studies are probably ‘‘overly’’ complex, with the
genetics per se possibly only explaining a small proportion of disease
incidence, unless coupled with other factors such as environmental
exposures. For example, T2D has a heritability estimate of ,50%
[24] while T1D has a much stronger familial component, with a
heritability estimate of ,90% [25]. Therefore, we expect that
whole-genome genotype-based disease risk assessment would
operate better in T1D than in previous studies of T2D. Altogether,
we are not proposing that the failure of previous studies indicates
that disease risk assessment is infeasible, rather that alternative
routes should be taken for a better evaluation of individual disease
risk assessment.
In the current study, we have attempted to address the issues
discussed above. First, rather than cherry-picking a few known
susceptibility loci for disease risk assessment, we utilized an entire
list of markers reaching a pre-defined statistical threshold for
association with a disease (for example, P,1610
25), even if the
majority of SNPs in that list have not been confirmed to be
genuine susceptibility loci. There is no doubt that some false
positive hits will arise, but we show that the computational
approaches used are in fact robust with the inclusion of these non-
contributing markers when also taking advantage of other markers
that are already established to be associated with the disease.
Second, we have utilized Support Vector Machine (SVM) [26], a
well-developed machine-learning technique in computer science.
Unlike traditional ‘‘number of risk alleles’’ approach or logistic
regression assuming independence between markers, our ap-
proach can both optimize prediction modeling and take advantage
of potential interactions between markers to achieve the optimal
binary predictive power. Finally, we have used T1D as an example
of our efforts for disease assessment. Unlike other common
diseases, such as T2D or coronary heart disease, a large fraction of
variance of genetic risk is already known for T1D: indeed, over
50% of the genetic susceptibility to T1D pathogenesis can be
explained by risk alleles in the major histocompatibility complex
(MHC) region alone, while the remaining genetic contribution has
been attributed to variants conferring more moderate risks [27].
The availability of multiple GWAS datasets for T1D, including
samples from different geographical sites, genotyped at different
locations and on different genotyping platforms (Affymetrix
Author Summary
An often touted utility of genome-wide association studies
(GWAS) is that the resulting discoveries can facilitate
implementation of personalized medicine, in which
preventive and therapeutic interventions for complex
diseases can be tailored to individual genetic profiles.
However, recent studies using whole-genome SNP geno-
type data for disease risk assessment have generally failed
to achieve satisfactory results, leading to a pessimistic view
of the utility of genotype data for such purposes. Here we
propose that sophisticated machine-learning approaches
on a large ensemble of markers, which contain both
confirmed and as yet unconfirmed disease susceptibility
variants, may improve the performance of disease risk
assessment. We tested an algorithm called Support Vector
Machine (SVM) on three large-scale datasets for type 1
diabetes and demonstrated that risk assessment can be
highly accurate for the disease. Our results suggest that
individualized disease risk assessment using whole-ge-
nome data may be more successful for some diseases
(such as T1D) than other diseases. However, the predictive
accuracy will be dependent on the heritability of the
disease under study, the proportion of the genetic risk that
is known, and that the right set of markers and right
algorithms are being used.
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the unbiased and systematic comparative evaluation of different
methods.
Results
Overview of the risk assessment algorithms
We tested a machine-learning approach called Support Vector
Machine (SVM, see Methods), as well as logistic regression (LR,
see Methods) in order to assess individual disease risk for type 1
diabetes (T1D) using three GWAS datasets (Table 1). SVM is one
of the most popular classifiers in the field of machine learning and
achieves state-of-the-art accuracy in many computational biology
applications [28]. In essence, SVM is a supervised machine-
learning algorithm that produces a linear boundary to achieve
maximum separation between two classes of subjects (cases versus
controls), by mathematical transformation (kernel function) of the
input features (SNP genotypes) for each subject. Unlike most
regression-based methods, SVM allows more input features (such
as SNPs or genes) than samples, so it is particularly useful in
classifying high-dimensional data, such as microarray gene
expression data [29]. We also applied LR as a control algorithm,
since it is widely used in genetic studies to model the joint effects of
multiple variants. Unlike previous disease assessment studies that
typically use genotype data from a handful of validated
susceptibility loci, we examined a large ensemble of SNP markers
with suggestive evidence for association with T1D, using a few P-
value cutoff thresholds ranging from 1610
23 to 1610
28, as well as
highly stringent quality control measures (see Methods). When
more relaxed P-value criteria are being used, the contributing
SNPs scatter across the genome; when more stringent criteria are
used (P,1610
28), only a few independent loci contribute
(assuming that all MHC markers represent a single locus).
Furthermore, we included the 45 known T1D susceptibility
markers [4] into the prediction models to ensure that their
predictive values were accounted for. Although these SNP lists
may contain some false positive loci that are not genuinely
associated with T1D, recent advancements in machine-learning,
such as regularization, have made classifiers more tolerant to
irrelevant input features [30]. Since we cannot completely
eliminate falsely associated loci from the list of predictors, our
goal is to include them in the prediction models (using various
thresholds) and then assess their influence on performance.
Evaluation of risk assessment models by within-study
cross-validation
To evaluate the sensitivity of various risk assessment models on
the number of predictor variables and the parameters of the
models, we performed five-fold cross-validation experiments on
the WTCCC-T1D dataset. During each cross-validation, 80% of
the samples (both cases and controls) were used to select a subset of
SNPs as predictors (see Methods), train a prediction model, and
then test on the remaining 20% of the samples. We stress here that
the results from a within-study cross-validation do not reflect the
true performance of risk assessment (see discussion below), but can
help select relevant parameters or thresholds to use. The AUC
(area under ROC curve) score was used to evaluate the
performance of risk assessment: the value ranges from 0.5 to 1,
with a higher number indicating better discriminative power
between cases and controls. We found that under various
thresholds for SNP selection, the SVM algorithm consistently
and slightly out-performed LR, achieving the highest AUC score
of ,0.9 (Table 2). The best performance seems to be achieved
when a P-value cutoff of 1610
25 is used for selecting SNPs for
SVM model training, corresponding to 399–443 SNPs in five
cross-validation experiments.
Evaluation of risk assessment models on independent
datasets
To assess the prediction model in an unbiased way, it is
important that independent datasets from different sources be
evaluated. This is a practical concern for all GWAS, since the
SNPs detected from the training dataset may be spuriously
associated with the disease, when cases and controls undergo
different DNA preparation protocols [31], when cases and controls
are genotyped in different batches, when population stratification
is present [32] or when cases share other traits that are unrelated
to the disease of interest (for example, cases often have a higher
average body mass index than controls when studying T2D [33]).
A within-study cross-validation design is not able to adjust for
these potential biases which are present in both the training and
testing data; therefore, we sought to test the risk assessment models
parameterized from the WTCCC-T1D dataset on additional
GWAS datasets (Table 1).
Since the CHOP/Montreal-T1D dataset was genotyped using
the Illumina platform, we generated whole-genome imputed
genotypes using MACH and then utilized shared markers present
on the Affymetrix array for the risk assessment. Additionally, we
examined a third GWAS dataset from the Genetics of Kidneys in
Diabetes consortium (GoKinD), which was genotyped on the same
platform as the WTCCC-T1D data, and we used shared markers
for the risk assessment. Since this dataset does not contain control
subjects, we supplemented this dataset with control subjects from
the UK Blood Service (UKBS) collection (a subset of samples from
WTCCC not used in the training phase). Similar to the analysis
presented above, we varied the P-value cutoff thresholds and
summarized the results for each threshold.
We found that the AUC score is 0.83 and 0.84 for the CHOP/
Montreal-T1D and GoKinD-T1D datasets, respectively, when
SNPs with P-value cutoff of 1610
25 were used in the SVM model
(Figure 1, Table S1 and Table S2). These values are notably lower
Table 1. Description of the three T1D datasets used in the study.
GWAS dataset Num of Cases Num of controls Array platform Purpose
WTCCC-T1D 1,963 1,480 Affymetrix Mapping 500K Prediction model training and parameter selection; evaluation
of predictive models trained on CHOP/Montreal-T1D
CHOP/Montreal-T1D 1,008 1,000 Illumina HumanHap550 Evaluation of predictive models trained on WTCCC-T1D, using
whole-genome imputed genotype data
GoKinD-T1D 1,529 1,458 Affymetrix Mapping 500K Evaluation of predictive models trained on WTCCC-T1D or
CHOP/Montreal-T1D
doi:10.1371/journal.pgen.1000678.t001
T1D Risk Assessment Using GWAS
PLoS Genetics | www.plosgenetics.org 3 October 2009 | Volume 5 | Issue 10 | e1000678than those obtained in cross-validation experiments, suggesting
that data differential biases might lead to the inflated performance
measures for both SVM and LR seen in Table 2. Nevertheless,
SVM consistently achieves higher accuracy than LR, and the
AUC scores in both datasets still indicate reasonably good
performance. Unlike the previous cross-validation results in
Table 2, we found that SVM demonstrate more clear advantage
over LR when evaluated by between-study validation. This
suggests that SVM may be less susceptible to differential biases
than LR through improved utilization of a subset of SNPs, so the
differences in performance is less when comparing results
generated on independent datasets versus those generated by
cross-validation. We also note that the performance advantage of
SVM over LR is less obvious, when models were tested on the
GoKind-T1D dataset. This could be due to several reasons: First,
the control group for the GoKind-T1D dataset was generated at
the same site as the WTCCC-T1D dataset, which may introduce
differential biases that are shared between the two datasets, with
LR being more susceptible to biases than SVM. Second, the
CHOP/Montreal-T1D dataset was imputed for proper genotype
matching, which may lead to systematic differences from the
WTCCC-T1D data from some less well imputed markers due to
platform differences. Third, the GoKind-T1D dataset contains
markers passing QC in both the WTCCC study and the GoKind
study, so they represent a subset of higher-quality markers, making
experiments on GoKind-T1D less susceptible to biases. To further
investigate this, we re-performed the experiments of training
models on WTCCC-T1D and testing on CHOP/Montreal-T1D,
using makers that passed QC in GoKind-T1D data (P,1610
25
threshold, 409 markers, as opposed to 478 markers): the AUC
score for LR increased to 0.82 but remained at 0.84 for SVM,
suggesting that inclusion of lower-quality markers led to degraded
performance for LR while the impact was less for SVM.
Furthermore, we investigated how the algorithms performed
when the models were trained on an independent dataset with
different size and ascertainment schema. As such, we built
prediction models from the imputed CHOP/Montreal-T1D
dataset using markers that are present on the Affymetrix arrays,
and then evaluated the model performance on the WTCCC-T1D
and the GoKind-T1D data (Figure 2, Table S3 and Table S4).
Despite the use of a different training dataset, SVM still
demonstrated an advantage over LR, with an AUC score of
0.85 on WTCCC-T1D and 0.84 on GoKind-T1D datasets,
respectively, when a P,1610
26 threshold is used for SNP
selection. Altogether, these results suggest that an SVM-based
risk assessment algorithm can accommodate differences in training
data and can generate consistent, robust results across different
datasets.
Predictive models have high specificity for T1D
Our analyses of three GWAS datasets demonstrate that the
SVM-based prediction model is highly reliable in separating T1D
cases from control subjects, but a remaining concern is whether
the model is specific to T1D, that is, does it tend to predict patients
with other diseases as potential T1D cases? To address this
concern, we applied the same risk assessment model trained on
Table 2. Evaluation of risk assessment models on the WTCCC-T1D dataset by five-fold cross-validation.
SNP
selection SVM (support vector machine) LR (logistic regression)
Min
#SNP
Max
#SNP
AUC
1 (SD
2) Sensitivity
3 (SD
2) Specificity
3 (SD
2) AUC
1 (SD
2) Sensitivity
3 (SD
2) Specificity
3 (SD
2)
P,1610
28 0.89 (0.017) 0.87 (0.018) 0.75 (0.041) 0.89 (0.016) 0.86 (0.026) 0.75 (0.035) 240 280
P,1610
27 0.89 (0.018) 0.87 (0.024) 0.75 (0.036) 0.88 (0.018) 0.86 (0.034) 0.76 (0.031) 286 328
P,1610
26 0.89 (0.018) 0.88 (0.019) 0.74 (0.041) 0.89 (0.022) 0.86 (0.033) 0.76 (0.044) 328 372
P,1610
25 0.89 (0.013) 0.88 (0.013) 0.73 (0.041) 0.88 (0.014) 0.85 (0.028) 0.75 (0.037) 399 433
P,1610
24 0.88 (0.012) 0.87 (0.021) 0.73 (0.026) 0.87 (0.011) 0.84 (0.016) 0.75 (0.030) 519 558
P,1610
23 0.86 (0.010) 0.85 (0.020) 0.69 (0.015) 0.80 (0.009) 0.77 (0.040) 0.69 (0.025) 1007 1085
1area under receiver operating characteristic curve.
2standard deviation.
3sensitivity and specificity were calculated with default cutoff of zero point.
doi:10.1371/journal.pgen.1000678.t002
Figure 1. Performance of risk assessment models trained on
the WTCCC-T1D dataset. For both the CHOP/Montreal-T1D and the
GoKind-T1D datasets, the SVM (support vector machine) algorithm
consistently outperforms LR (logistic regression), and the best
performance is achieved when SNPs were selected using P-value cutoff
of 1610
26 or 1610
25.
doi:10.1371/journal.pgen.1000678.g001
T1D Risk Assessment Using GWAS
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WTCCC, including bipolar disorder (BD), coronary heart disease
(CAD), Crohn’s disease (CD), hypertension (HT), rheumatoid
arthritis (RA) and type 2 diabetes (T2D). This analysis is especially
interesting, since these diseases include a different subtype of
diabetes and two autoimmune diseases (CD and RA), which may
share some susceptibility loci with T1D.
By testing the SVM-based prediction model for T1D on other
six disease cohorts, we found that with the exception of RA, the
specificity values are indeed encouraging, ranging from 71.6% for
T2D to 74.8% for BD (Figure 3). The specificity for RA, an
autoimmune disease with a large genetic susceptibility component
from the MHC region, is 57.6%, confirming that T1D and RA do
share some genetic risk factors and susceptibility pathways. Besides
MHC, the PTPN22 locus on 1p13 is well known to contribute to
both T1D and RA [34,35], and the WTCCC study reported three
additional shared susceptibility loci (IL2RA on 10p15, PTPN2 on
18p11 and chromosome 12q14 region) [36]. For other diseases,
these specificity values are at similar range or slightly higher than
that for the UK Blood Service (UKBS) control cohort, so a patient
affected by diseases unrelated to T1D is not more likely to be
predicted as a T1D patient, compared to a control subject. In
conclusion, our analyses suggest that the risk assessment model
built for T1D is specific to that disease.
Understanding the behavior of the risk assessment
models
To investigate in depth why the SVM algorithm works in the
setting of T1D risk assessment, we next evaluated several different
forms of the risk assessment models by modifying the predictors or
the model parameters. The following six different types of analyses
helped us better understand the source of the improved
performance of the SVM algorithm.
1) We found that elimination of SNPs in the MHC region
severely deteriorate the performance of disease risk assess-
ment. Since a large fraction of the genetic contribution to
T1D can be explained by risk alleles in the major
histocompatibility complex (MHC) region (,50%) [37], we
tested whether using SNPs outside of the MHC region had
any predictive value. This analysis helped identify the relative
contribution of MHC-linked SNPs with major effects and
other SNPs with moderate effects on disease risks. For this
analysis, we removed all the SNPs located from 25 Mb to
34 Mbonchromosome6:thisgenomicspanislargerthanthe
actual MHC region in order to ensure that SNPs outside
MHC but in linkage disequilibrium (LD) with MHC markers
are not used in the prediction model. With the P,1610
25
threshold, a large proportion of the SNPs (,83%) were
removed from the prediction models. We then tested the
performance of the SVM and LR algorithms using the same
approach described above. As expected, using SNPs outside
of the MHC region do not confer satisfactory performance in
disease risk assessment; for example, for the GoKind-T1D
data, using SNPs with P,1610
25, the AUC score for SVM
dropped from 0.84 to 0.64, whereas the AUC score for LR
dropped from 0.81 to 0.65. Similar results were obtained for
the CHOP/Montreal-T1Ddataset. Therefore, elimination of
SNPs with major effects severely attenuates the performance
ofdisease riskassessment;ontheotherhand,ouranalysesalso
confirmed that SNPs outside the MHC region do explain a
portion of the genetic susceptibility to T1D and can provide
complementary information for risk assessment. These results
also suggest that whole-genome genotypes provide more
information than the costly HLA-typing techniques used in
the clinical settings, even for the purpose of risk assessment of
MHC-linked diseases such as T1D.
2) We found that pruned sets of independent markers lead to
worse performance. The risk assessment model used sets of
markers reaching pre-defined thresholds, which may include
Figure 2. Performance of risk assessment models trained on
the CHOP/Montreal-T1D dataset. For both the WTCCC-T1D and the
GoKind-T1D datasets, the SVM (support vector machine) algorithm
consistently outperforms LR (logistic regression), and the best
performance is achieved when SNPs were selected using P-value cutoff
of 1610
26 or 1610
25.
doi:10.1371/journal.pgen.1000678.g002
Figure 3. Specificity of the SVM-based risk assessment models.
The risk assessment models were parameterized on the WTCCC-T1D
dataset and evaluated on other disease cohorts from WTCCC, including
bipolar disorder (BD), coronary heart disease (CAD), Crohn’s disease
(CD), hypertension (HT), rheumatoid arthritis (RA), and type 2 diabetes
(T2D). The specificity measure was calculated with default cutoff of zero
point. Except for RA, the specificity measures of the prediction model
are comparable for other diseases as that for the control subjects.
doi:10.1371/journal.pgen.1000678.g003
T1D Risk Assessment Using GWAS
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of handling the inter-marker correlation structure, whereas we
used regularization techniques [38] in the LR model for
addressing this problem. (We did not use stepwise regression
model because it is highly unstable when the number of
predictor variables is large.) Since many markers are in high
LD with each other, we can prune this list to generate a
smaller set of markers that have pairwise r
2 less than a certain
threshold. Intuitively, using fewer markers should lead to
information loss and therefore lower predictive power, but we
were interested in specifically quantifying this magnitude of
loss. We trained a SVM-based prediction models on the
WTCCC-T1D dataset using SNPs with P,1610
25 that were
prunedbyvariousthresholds:whenr
2thresholdof0.1,0.2,0.5
and 0.8 were used, the AUC scores in the testing dataset were
0.65 (63 SNPs), 0.76 (75 SNPs), 0.79 (153 SNPs) and 0.83 (268
SNPs), respectively. We next used the P,1610
28 criteria to
select SNP markers, and then performed the same set of
computational experiment again: when r
2 threshold of 0.1,
0.2, 0.5 and 0.8 were used, the AUC scores in the testing
dataset were 0.67 (55 SNPs), 0.76 (60 SNPs), 0.79 (113 SNPs)
and 0.82 (184 SNPs), respectively. Altogether, our analyses
suggest that the use of independent markers does indeed lose
information which is important for risk assessment. Therefore,
many previous studies that use only the single most significant
SNP per associated loci did not capitalize on all the available
genotype information in an optimal manner.
3) We found that radial kernel performs better than linear
kernel in SVM. The SVM algorithm that we have used
adopted a default radial kernel to transform genotype scores
(see Methods), as it is a widely used kernel in most SVM
applications. To determine if the data transformation leads
to better performance, we also evaluated the SVM
algorithm without any transformation, that is, with a linear
kernel. Similar to previous experiments, we trained a SVM-
based assessment models on the WTCCC-T1D dataset
using SNPs with P,1610
25. We found that the AUC scores
of SVM using linear model are less than those with radial
kernel for the GoKind-T1D dataset (0.77 vs 0.84),
suggesting that linear combination of predictors (SNPs) is
less optimal than higher-order transformation of predictors
when separating cases versus controls using SNP genotypes.
Similar results were obtained for the CHOP/Montreal-T1D
dataset. These observations are consistent with recent
findings on the genetic interactions between MHC loci
and non-MHC loci for conferring T1D risk [4]. However,
unlike LR, the SVM model suffers from poor interpretabil-
ity, that is, one cannot identify specific pair of SNPs that
interact with each other from the model parameters.
Additionally, we note that two types of interactions may
be important contributors to the risk assessment: statistical
interactions between unlinked SNPs (that contribute to
liability scale in a non-additive fashion), as well as haplotype
interactions (correlated SNPs that are on the same haplotype
and are not captured by a model with additive predictors).
4) We investigated the relative effect of modeling correlated
SNPs in MHC and non-MHC regions. Our results so far
demonstrate that handling of interactions between SNPs, as
well as utilizing SNPs with major effects in the MHC region,
are important for risk assessment, but their relative
contribution is unknown. To test the effect of incorporating
non-MHC loci and modeling correlated SNPs for the
performance of LR and SVM, respectively, we next
performed several variations of the pruned analysis, with
the P,1610
25 threshold for selecting SNPs and with
pairwise r
2,0.2 threshold for pruning independent sets of
SNPs in GoKind-T1D dataset (Table 3). First, we used
pruned list of MHC SNPs only, so only independent
markers contribute to risk assessment: the AUC for LR and
SVM is 0.70 and 0.74, respectively. The decreased
performance could be due to the inability to model
interaction effects between correlated SNPs, but it also
could be due to the (unknown) causal variants being tagged
less well in the pruned set. Second, we used pruned list of
MHC SNPs plus all non-MHC SNPs: the AUC for LR and
SVM is 0.74 and 0.75, respectively, suggesting that
additional non-MHC loci contribute to improved perfor-
mance but the effects are more obvious for LR. Third, we
used MHC SNPs only but without pruning: the AUC for
LR and SVM is 0.78 and 0.81, respectively, suggesting that
both LR and SVM benefit from incorporating correlated
SNPs within MHC, which play a more prominent role in
the risk modeling than non-MHC markers. Altogether, these
analyses suggest that a key contributor to the performance of
the SVM algorithm is the better modeling of LD structure
among MHC SNPs.
5) We found that an alternative allele coding scheme without
assuming genetic model has similar results. In the previous
analysis, for each SNP, we coded the three different
genotypes (homozygous major allele, heterozygotes, homo-
zygous minor allele) as 0, 1 and 2, respectively. To
investigate the sensitivity of prediction models on allele
coding, we next explored an alternative coding scheme, by
generating two dummy variables (0 or 1) for each SNP,
indicating the presence or absence of an allele. This coding
scheme effectively doubles the number of predictor
variables, but without assuming an additive risk model for
each SNP. We tested the new coding scheme on the
GoKind-T1D dataset, and found that the AUC score
remained the same as 0.84. For the CHOP/Montreal-T1D
dataset, the AUC Score slightly decreased from 0.83 to 0.82.
Therefore, relaxing genetic model assumptions do not
appear to have a major impact on the performance of risk
models.
6) We found that the collection of known T1D susceptibility
loci has poor performance. Recent progress with GWAS has
enabled the identification of dozens of confirmed and
replicated T1D susceptibility loci [3,4]. As a negative control
experiment, we tested the performance of risk assessment
using only established susceptibility loci. This analysis is
Table 3. Comparative analysis of prediction models by
including different sets of markers.
Marker selection (P,1610
25) # markers AUC
1 (LR) AUC
1 (SVM)
All (MHC and non-MHC) SNPs 409 0.81 0.84
MHC SNPs 338 0.78 0.81
Non-MHC SNPs 71 0.65 0.64
Pruned MHC and non-MHC SNPs
2 82 0.74 0.76
Pruned MHC SNPs
2 27 0.70 0.74
Pruned MHC SNPs
2 and not pruned
non-MHC SNPs
98 0.74 0.75
1area under receiver operating characteristic curve.
2SNPs are pruned using pairwise r
2 threshold of 0.2.
doi:10.1371/journal.pgen.1000678.t003
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assessment studies, in that the prediction model only
considers known information, while ignoring other poten-
tially associated loci. We built risk assessment models around
the WTCCC-T1D dataset, using 45 known T1D suscepti-
bility SNPs compiled from a recent meta-analysis [4], after
excluding one locus on chromosome X (Table S5). Note that
only one representative SNP from the MHC region is used
in the assessment models. For the SVM algorithm, the AUC
scores are 0.66 for the GoKind-T1D dataset and 0.65 for
the CHOP/Montreal-T1D dataset, indicating a limited
value of risk assessment using a reduced number of validated
SNPs. For the LR algorithm, the AUC scores are 0.68 for
both the GoKind-T1D and the CHOP/Montreal-T1D
datasets, which are slightly higher than those obtained using
the SVM algorithm. Nevertheless, the relatively modest
performance is not unexpected, and echoes what has already
been observed in T2D disease assessment studies. Collec-
tively, this analysis confirms that one of the keys to success is
the use of a large ensemble of loci associated to the disease of
interest, at the cost of including potential false positive loci.
Discussion
In this study, we tested the plausibility of building a classifier
and using a large number of SNPs for disease risk assessment on
three large T1D datasets. In general, the SVM algorithm achieved
satisfactory performance when hundreds of SNPs were included in
prediction models, with AUC scores of ,0.84 for predicting
disease risk for T1D in several GWAS datasets. In contrast, the
SVM or the LR algorithm achieved only an AUC score of
0.66–0.68 when 45 known T1D susceptibility loci were used. This
difference clearly indicates that the predictive value lies in utilizing
a large number of SNPs in a sophisticated machine-learning
algorithm. We note that another recent study also reported that
using thousands of SNPs improve the performance of disease risk
assessment compared to using fewer SNPs for diseases studied by
WTCCC [39], although the study used a cross-validation design.
On the other hand, we observed a decrease in the predictive
accuracy when too many SNPs were used, suggesting an upper
bound of the number of SNPs for T1D risk assessment before
noises from falsely associated markers lead to degraded perfor-
mance. However, we caution that this upper bound depends on
the sample size and the power of the study to rank truly associated
SNPs higher than background noises.
One of the major differences between the two classifiers used in
the study is in their capability of handling main and interaction
effects. SVM takes into account both effects, while LR aims to
model linear main effects but ignores interaction. As an example,
for a simple interaction model with two risk loci A and B, the
disease risk will increase significantly only if A=0 and B=1 or
A=1 and B=0. Such interaction can be captured by SVM using
various kernels, but not by the simple LR model. In our study, we
observed that SVM outperformed LR by taking into account both
main and interaction effects, implying that both genes and their
interactions contribute to T1D. This is particularly important for
T1D, as many previous studies have already shown that risk from
MHC and non-MHC regions accumulates at a rate less than
expected from the model of multiplicative effects, and that the
relative risks for non-MHC loci are reduced when MHC-related
risk is high [4]. Additionally, we also found that better modeling of
LD structure within MHC (haplotype interactions) play a major
role in SVM-based risk modeling. However, these issues have been
largely ignored in previous simulation studies on disease risk
assessment [13,15,40], probably because the appropriate modeling
of interaction effect is by itself not well understood. Nevertheless,
some previous real-data studies already documented the impor-
tance of interactions effects in prediction model for quantitative or
qualitative phenotypes: for example, Lee et al have applied a
MCMC approach that takes into account of within and between
loci interactions, for phenotype prediction in heterogeneous stock
mouse population in a cross-validation design [41]. Therefore,
while simulation studies are useful in drawing general qualitative
conclusions such as that predictive accuracy increases with
heritability, their quantitative findings may not be accurate
because of the ‘‘non-interaction’’ assumptions they have to make.
Although we have limited understanding of the interaction
patterns of variants underlying common and complex diseases,
we argue that the previous simulation results may not necessarily
reflect real-world scenario.
Although the implementation of individual risk assessment in
clinical settings could have major economic benefit to the public
health at the population level [42], the clinical utility of individual
risk assessment depends on a few factors that must be taken into
account. First, the appropriateness of individual risk assessment is
dependent on the genetic etiology of the disease [16]. Given that
the vast majority of the phenotypic variation in T1D can be
explained by genetic factors, T1D assessment would have a strong
basis for being applied in clinical settings: in fact, HLA-typing,
albeit being both costly and imperfect, is now being used in clinical
settings for assessing T1D risk for siblings of affected patients.
Unlike T1D, where genetic factors are estimated to explain ,90%
of the phenotypic variance, the heritability estimates for T2D are
less than 50% [24]. Therefore, even if all genetic risk factors are
identified ultimately for T2D and a perfect SNP-based prediction
model is available for the disease, they would have less impact in a
clinical setting than T1D prediction models.
Second, the clinical utility of a risk assessment model depends on
the disease prevalence at the particular clinical setting. Using the
sensitivity and specificity measures for the WTCCC-T1D model on
CHOP/Montreal-T1D datasets (Figure S1), we evaluated three
scenarios of diagnostic testing using SNP arrays: (1) general
population (disease prevalence=0.4%), (2) siblings of affected
patients (disease prevalence=6%), (3) siblings of early-onset patients
who developed diabetes before 5 yrs of age (disease preva-
lence=13%). When a general population is screened by the
prediction model,the positivepredictive valuesare relativelymodest,
indicating that the risk assessment model is not of much utility for
population-level screening. However, in a realistic clinical setting,
where siblings of affected patients are evaluated, the WTCCC-T1D
prediction model achieves a positive predictive value of 16% and a
negativepredictive value of almost100%;thatis,,16% of predicted
positive patients will eventually develop the disease, while very few
predicted negative patients will develop the disease, with overall
accuracy of 93%. Finally, for siblings of early-onset patients, the
positive predictive value reaches 31%, while a strong negative
predictive value of 96% can still be retained with an overall
prediction accuracy of 87%. Although T1D has a large genetic
contribution from risk alleles in the MHC region, it is well known
that costly HLA-typing per se is not sufficient for T1D risk assessment
with high accuracy. Based on our results, we envision that low-cost
SNP genotyping platforms may have the potential to replace HLA-
typing in assessing T1D risk in clinically relevant settings.
Third, for a given disease, the best assessment model and the
most optimal number of predictors (SNPs) may depend on the
distribution of effect sizes. Some autoimmune diseases, such as
T1D, have major-effect loci (MHC) that explain a large
proportion of the genetic risk (,50% for T1D), with additional
T1D Risk Assessment Using GWAS
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Therefore, for these diseases, the collection of SNPs with
P,1610
25 in a given GWAS probably already captured the vast
majority of the variance for genetic susceptibility, and can lead to
good prediction performance. Therefore, diseases such as T1D
might represent an extreme example where genotype-based risk
assessment is clinically feasible. In contrast, MHC loci play a much
less important role or no role in CD or T2D susceptibility, so a
much more liberal P-value threshold may be required for SNP
selection, to ensure the capture of a large fraction of the genetic
risk in prediction models. This step will likely include more
markers that are falsely associated with the disease in prediction
models, and may dilute the contribution from genuinely associated
loci. Taking interception from independent datasets (for example,
SNPs with P,0.05 in two GWAS) may be explored for risk
assessment on these diseases. Furthermore, diseases such as
psychiatric disorders do not appear to even have any major-effect
loci that are common, so accurate assessment of disease risk may
require even more markers or whole-genome markers.
Finally, besides genetic factors, other risk factors that are specific
for each disease need to be accounted for in order to make an
accurate risk assessment. Early onset diseases such as T1D may be
less dependent on non-genetic factors. In contrast, T2D is a late-
onset disease with a range of known environmental risk factors
contributing to its pathogenesis, and may be predicted more
accurately if such factors are also used. Therefore, a comprehen-
sive disease risk assessment model should try to take into account
environmental risk factors, such as diet and smoking habits, as well
as other predictor variables such as gender and BMI in order to
improve performance. These factors are most likely disease-
specific and can be identified from cumulative epidemiological
studies on each disease. We note that the SVM model used in our
study can readily take into account additional predictor variables.
In conclusion, the results from recent GWAS have yielded
enormous amounts of data that can be mined and utilized for
better understanding of human disease, including disease risk
assessment using genetic profiles. Although only a small fraction of
risk factors for complex diseases have been identified to date, other
variants with moderate effects are present in the GWAS data, and
a risk assessment algorithm should be able to take advantage of
these variants for improved performance. We expect that methods
that utilize whole-genome data, rather than a few ‘‘validated’’
susceptibility loci, could improve predictive accuracy and have
greater impact on health care in the future; for example, by
applying personalized intervention strategies on newborns who are
at risk of developing T1D, we may reduce their risk of developing
the disease or be better prepared to treat the disease. This would
be feasible if these individuals can be identified from genetic risk
profiles, using algorithms (such as the SVM algorithm proposed in
this study) with high positive predictive values.
Methods
Description of study subjects
Type 1 Diabetes (T1D) GWAS dataset from WTCCC: We
accessed the 500K Affymetrix chip genotype data from WTCCC on
,1,500 samples from the 1958 British Birth Cohort, ,1,500 samples
from the UK Blood Service Control Group, as well as ,2,000
samples each from the following disease collections: type 1 diabetes
(T1D), type 2 diabetes (T2D), rheumatoid arthritis (RA), inflamma-
tory bowel disease (IBD), bipolar disorder (BD), hypertension (HT),
coronary artery disease (CAD), as previously described [36]. For each
dataset, we have downloaded the genotype calls generated by the
Chiamo algorithm, and we have applied the default confidence score
of 0.9 to keep the high-quality genotype calls. In addition, we
removed the 30,956SNPmarkersfailingQCthreshold (duetooneof
three criteria), as specified in the website. For each dataset, we
observed the same recommended sample exclusion criteria, as
specified in the various ‘‘exclusion-list’’ files in the data repository.
T1D GWAS dataset from GoKinD: The Genetics of Kidneys in
Diabetes (GoKinD) study [43,44] T1D case data were download-
ed from dbGaP [45]. This dataset consists of T1D cases only
(about half have diabetic nephropathy but half without nephrop-
athy). Therefore, we subsequently used the UK Blood Service
dataset from WTCCC as control subjects for the risk assessment
sensitivity/specificity analysis. Both the case and control genotypes
in this dataset were independent and not used in the prediction
model building.
T1D GWAS datasets from CHOP and Montreal: The third
T1D case series used in our study was genotyped at the Children’s
Hospital of Philadelphia (CHOP), and a subset of this cohort has
been previously described [46]. The dataset contains 1,008 T1D
subjects and 1,000 control subjects. The T1D families and cases
were identified through pediatric diabetes clinics at the Children’s
Hospital of Montreal and at CHOP. All control subjects were
recruited through the Health Care Network at CHOP. The multi-
dimensional scaling analysis on genotype data was used to identify
subjects of genetically inferred European ancestry. All subjects
were genotyped at ,550,000 SNPs by the Illumina Human-
Hap550 Genotyping BeadChip; to apply the prediction model on
these subjects, we subsequently used genotype imputation (see
below) to generate imputed genotypes on these subjects.
Genotype imputation on Illumina arrays
We used the Markov Chain Haplotyping (MACH) software
(http://www.sph.umich.edu/csg/abecasis/MaCH/index.html)
for genotype imputation on markers that are present in the
Affymetrix array from WTCCC, but not present in the Illumina
HumanHap550K arrays used by us. The default two-step
imputation procedure is adopted for imputation: (1) In the first
step, 500 randomly selected subjects of European ancestry are
used to estimate the best model parameters. This model includes
both an estimate of the ‘‘error’’ rate for each marker (an omnibus
parameter which captures both genotyping error, discrepancies
between the imputed platform and the reference panel, and
recurrent mutation) and of ‘‘crossover’’ rates for each interval (a
parameter that describes breakpoints in haplotype stretches shared
between the imputed and the reference panel). The software
requires several input files for SNPs and phased haplotypes; we
used the HapMap phased haplotypes (release 22) on CEU
subjects, as downloaded from the HapMap database (http://
www.hapmap.org). (2) In the second step, we used the optimized
model parameters to impute the genotypes on .2 million SNP
markers in HapMap data. The default Rsq threshold of 0.3 in the
mlinfo file was used to flag unreliable markers used in the
imputation analysis, and the posterior probability threshold of 0.9
was used to flag unreliable genotype calls. The imputed genotype
data were then checked for strand orientation (since the Affymetrix
genotype data from WTCCC may not align correctly with the
HapMap phased genotype data) and inconsistencies were resolved
using the flip function in the PLINK software [47].
Disease risk assessment model building
For our purposes, genetic profiles on p SNPs for n individuals
may be summarized by an n*p matrix G=(gij), where gij denotes
the genotypic value of SNP i in individual j. The genotype data
are encoded by 0, 1 and 2. In genome wide association studies,
data for each individual consist of a genetic profile Gi=(gi1,…, gip)
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variables Gi and response variable yi. Based on current genotyping
technologies, the number of SNPs p typically can be as large as
several hundred thousands, whereas the number of individuals n is
several thousands in typical genetic studies. Therefore, in our
comparison of prediction methods, we use only the list of markers
reaching a pre-defined statistical threshold of association with
disease. As a result, the number of SNPs used for disease
prediction is substantially reduced to at most one or two thousands
in our studies.
In machine learning, a predictor or classifier is built from past
experience and is used to make predictions of unknown future. In
our case, a trained classifier partitions the space of genetic profiles
into two disjoint and exhaustive subsets, cases and controls, such
that for a DNA sample with genetic profile g=(g1,…, gp), the
classifier can accurately predict if it is a case sample or a control
sample. With the large amount of WTCCC case-control data
available for training, we were able to build a predictor with good
accuracy that we subsequently applied on two independent test
cohorts. While the challenges ahead in translating the emerging
genomic knowledge into clinical practice, we envision the
approach we have taken to be an important step towards these
goals.
Many classification methods have been developed and applied
to various domains. No classifier could show dominant perfor-
mance consistently in all applications. In our comparison study, we
compared the efficacy of two representative ones, logistic
regression (LR) and support vector machine (SVM). A logistic
regression model and its variants are one of the most widely used
approaches in genetic data analysis. They are simple but often
provide an adequate and interpretable description of how the
inputs affect the output. In addition, simpler linear methods work
as well or better for microarray classification problems where the
number of candidate predictors exceeds the number of samples by
orders of magnitude [48]. We consider the logistic regression
model, which models the posterior probabilities of being a case or
a control via a linear combination of gi1,…, gip. Formally,
log
Pr(y~1jG~g)
1{Pr(y~1jG~g)
~b0zb1g1z:::zbpgp
Under the LR model (b0,b1,…,bp), the probability of being cases
(y=1) for a genetic profile is exp(b
Tg)/(1+exp(b
Tg)), where b=(b0,
b1,…, bp) and g=(1, g1,…, gp)
T. Given the training data, the LR
model is fit to get a maximum likelihood estimate (MLE) of b, and
this estimate can be used for future prediction. It is noted that
giM{0,1,2} is treated as a numeric value.
The LR model has the advantage that the main effect of each
SNP to the phenotypes has a linear and interpretable description.
The effect of each SNP can be naturally interpreted as the increase
of the log odds ratio in favor of being a case when the count of risk
allele changed by 1. One caveat of using LR model in GWAS is
that linkage disequilibrium dependency of input markers may
make the parameter estimation unstable. To address this issue, we
imposed a L
‘2 regularization on the LR model building [38]. We
implemented our LR model based on the stepPlr package in R
developed by Park and Hastie [49].
The second classifier that we have applied is the support vector
machine (SVM) algorithm [26,50]. SVM is one of the most
popular supervised classifiers in the field of machine learning and
has been widely used in many bioinformatics applications. SVM
aims to find an optimal separating hyperplane between cases and
controls and this is achieved by two key factors: large margin
separation and kernel functions. The classification problem is
formulated by SVM as the optimization problem
maxC
b,b0,jjbjj~1
subject to yi(b
Tgzb0)i§C,i~1,:::,N
When the samples are linearly separable, the optimal hyperplane is
the one that creates the biggest margin C between the training points
for cases and controls. When the samples in feature space (g1,…, gp)
are not linearly separable, certain overlap can be allowed by
introducing the slack variable j~(j1,j2,:::,jN) and the constraint is
modified as yi(b
Tgzb0)i§C{ji Vi,ji§0,
XN
i~1 jiƒconstant.
More importantly, linear separability can be obtained in an
expanded input feature space h(g) by using kernel functions.
Specially for SVM, the explicit transformation h(g) is not
needed and only knowledge of the kernel function is required
K(g, g9)=,h(g), h(g9)., which computes inner products in the
expanded feature space. Two popular kernel functions in the SVM
literature are
Polynomial kernel of degree d: K(g,g0)~(kzvg,g0w)
d
Radial kernel: K(g,g0)~exp({jjg{g0jj
2=2)
When k~0 and d~1, it is a special case of the polynomial kernel
called the linear kernel, which operates in the original input feature
space. Using non-linear kernel functions, SVM can produce
nonlinear boundaries to separate two classes of objects by
constructing equivalent linear boundaries in an expanded input
feature space. Such transformations usually increase accuracy
considerably on one hand, but on the other hand the transforma-
tions cause poor interpretability, namely, it is not clear how the
inputs affect the output even though high accuracy is obtained.
In the case of disease risk assessment, SVM constructs an
optimal linear boundary (prediction model) in an expanded input
feature space (in our case, transformed genotype calls for a
collection of SNPs). New features, or a transformation of input
features (SNP genotypes), can be derived by using the kernel
function [50], with the goal of making inputs linearly separable.
However, no biological interpretation can be attached to each
predictor variable (SNP) in the prediction model. We implemented
the SVM model using the machine learning package e1071 in R. It
is based on the popular SVM library LIBSVM [51]. For model
building, we used all default options including the radial kernel. To
assess the effect of data transformation implemented in the radial
kernel, we have also explored the use of the linear kernel and
compared their predictive performance.
SNP data processing and coding
For the case-control datasets, to reduce the potential concern on
stratification or batch effects, we applied highly stringent quality
control measures to select SNPs to use in the prediction models. We
applied several quality filters, including call rate .95%, minor allele
frequency.5% and Hardy-Weinberg equilibrium P-value .1610
23,
for the selection of SNPs. We used the EigenStrat algorithm [52] on
genotype data, and selected subsets of SNPs reaching pre-defined P-
value thresholds to build prediction models, including P,1610
28,
P,1610
27,P ,1610
26,P ,1610
25,P ,1610
24 and P,1610
23.
Additionally, only autosomal markers were used in our prediction
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removed SNPs from the training data that are not present in the
testing data (for example, SNPs not in HapMap or SNPs without
known dbSNP identifiers). Genotypes with missing values were
imputed by sampling from the allele frequency distribution. We
coded homozygous major allele, heterozygotes and homozygous
minor allele as 0, 1 and 2, respectively.
Performance evaluation
The simplest and most widely used method for estimating
prediction error may be K-fold cross-validation. However, due to
the data differential biases discussed in the paper, we caution that
cross-validation approach may severely inflate the true predictive
value. In K-fold cross-validation, the data is split into K roughly
equal-sized parts; for the kth part of the data, the classifier is
trained based on the other K-1 parts of the data and then used to
predict the kth part of the data. The process is iterated for k=1,2,
…, K and predictions for all data are obtained. The predictions are
then used for estimating prediction performance of the classifier.
Typical choices of K are 5 or 10. We do five-fold cross-validation
to compare performance of the two classifiers over the seven case-
control disease datasets. Specifically, we measure accuracy,
sensitivity and specificity defined as follows,
Accuracy: (TPzTN)=(TPzFNzTNzFP)
Sensitivity: TP=(TPzFN)
Specificity: TN=(TNzFP)
where TP, TN, FP and FN denote the number of true positives,
true negatives, false positives and false negatives, respectively. Note
that since prediction algorithms typically give quantitative
assessment, we used the default cutoff of zero point for the
sensitivity and specificity calculation.
In addition, we also evaluated the performance by the area
under receiver operator characteristic (ROC) curve scores (AUC
scores). ROC is a widely used means to evaluate the discrimination
ability of binary classification methods when the test results are
continuous measures. ROC curves display the relationship
between sensitivity (true positive rate) and 1-specificity (false
positive rate) across all possible threshold values that define the
positivity of a condition (in our case, whether a subject has T1D
diagnosis). The AUC scores may range from 0.5 to 1, with a
higher score indicating better discriminatory power.
Furthermore, to measure the performance of a prediction model
in clinical settings, we calculated the positive predictive value
(PPV) and negative predictive value (NPV), which incorporate the
disease prevalence in the testing population. These two values
were calculated as:
PPV~sensitivity   prevalence=
½sensitivity   prevalencez(1{specificity)   (1{prevalence) 
and
NPV~specificity   (1{prevalence)=
½(1{sensitivity)   prevalencezspecificity   (1{prevalence) :
Supporting Information
Figure S1 Illustration on how positive predictive value (PPV)
and negative predictive value (NPV) vary with respect to disease
prevalence in a testing population. The figure is based on
sensitivity and specificity estimates from WTCCC-T1D data set
on CHOP-T1D data when P,1610
25 is used. The three vertical
lines represent three different scenarios of clinical testing, with
disease prevalence of 0.4%, 6%, and 13%, respectively.
Found at: doi:10.1371/journal.pgen.1000678.s001 (0.02 MB TIF)
Table S1 Prediction performance of the WTCCC-T1D trained
model on the CHOP/Montreal-T1D datasets.
Found at: doi:10.1371/journal.pgen.1000678.s002 (0.02 MB PDF)
Table S2 Prediction performance of the WTCCC-T1D trained
model on the GoKind-T1D datasets.
Found at: doi:10.1371/journal.pgen.1000678.s003 (0.02 MB PDF)
Table S3 Prediction performance of the CHOP/Montreal-T1D
trained model on the WTCCC-T1D datasets.
Found at: doi:10.1371/journal.pgen.1000678.s004 (0.02 MB PDF)
Table S4 Prediction performance of the CHOP/Montreal-T1D
trained model on the GoKind-T1D datasets.
Found at: doi:10.1371/journal.pgen.1000678.s005 (0.02 MB PDF)
Table S5 A list of 46 previously validated T1D susceptibility loci
reported in the meta-analysis by Barrett et al.
Found at: doi:10.1371/journal.pgen.1000678.s006 (0.12 MB PDF)
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